The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 19, 2016
Filed:
Dec. 03, 2013
Applicant:
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Washington, DC (US);
Inventors:
Sanjay A. Desai, Potomac, MD (US);
Ajay D. Pillai, Hyderabad, IN;
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/41 (2006.01); A61K 31/44 (2006.01); C07D 513/04 (2006.01); A61K 31/165 (2006.01); A61K 31/4155 (2006.01); A61K 31/423 (2006.01); A61K 31/4245 (2006.01); A61K 31/433 (2006.01); A61K 31/4355 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/4741 (2006.01); A61K 31/4745 (2006.01); A61K 31/50 (2006.01); A61K 31/554 (2006.01); A61K 45/06 (2006.01); C07D 263/57 (2006.01); C07D 281/16 (2006.01); C07D 413/14 (2006.01); C07D 417/06 (2006.01); C07D 491/048 (2006.01); C07D 403/08 (2006.01); C07D 498/04 (2006.01);
U.S. Cl.
CPC ...
C07D 513/04 (2013.01); A61K 31/165 (2013.01); A61K 31/4155 (2013.01); A61K 31/423 (2013.01); A61K 31/4245 (2013.01); A61K 31/433 (2013.01); A61K 31/437 (2013.01); A61K 31/4355 (2013.01); A61K 31/4439 (2013.01); A61K 31/4741 (2013.01); A61K 31/4745 (2013.01); A61K 31/50 (2013.01); A61K 31/554 (2013.01); A61K 45/06 (2013.01); C07D 263/57 (2013.01); C07D 281/16 (2013.01); C07D 403/08 (2013.01); C07D 413/14 (2013.01); C07D 417/06 (2013.01); C07D 491/048 (2013.01); C07D 498/04 (2013.01);
Abstract
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein Rto Rare as described herein.